TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Allergan Just Announced Two Significant Deals
VIDEO

Allergan Just Announced Two Significant Deals

PRESS RELEASES

Assembly Biosciences To Wind-Down Microbiome Program

PRESS RELEASES

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Assembly Biosciences Appoints Nicole S. White, PhD, As Senior Vice President Of Pharmaceutical Development And Manufacturing

PRESS RELEASES

Assembly Biosciences And Door Pharmaceuticals Sign Collaboration And Option Agreement To Develop A Novel Class Of HBV Core Protein Modulators

PRESS RELEASES

Assembly Biosciences Presents Data From HBV Core Inhibitor Programs In Poster Sessions At The 2020 AASLD The Liver Meeting Digital Experience™

PRESS RELEASES

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Multiple Abstracts Highlighting Assembly Biosciences' Hepatitis B Core Inhibitor Development Programs Accepted For Presentation At The 2020 AASLD The Liver Meeting Digital Experience™

PRESS RELEASES

Assembly Biosciences Appoints Gina Consylman To Board Of Directors

PRESS RELEASES

Assembly Biosciences CEO Dr. John McHutchison Named Recipient Of The Prestigious Advance 2020 Global Impact Award

PRESS RELEASES

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Clinical Data From Assembly Biosciences' HBV Core Inhibitors Presented At The Digital International Liver CongressTM EASL 2020

PRESS RELEASES

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Assembly Biosciences Announces FDA Fast Track Designation Granted To ABI-H2158 For The Treatment Of Chronic Hepatitis B Virus Infection

PRESS RELEASES

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 For Chronic Hepatitis B Infection

PRESS RELEASES

Preclinical Data From Assembly Biosciences' Immuno-Oncology Microbiome Program Featured At AACR's Virtual Annual Meeting II

PRESS RELEASES

Assembly Biosciences Regains Worldwide Rights To Microbiome Gastrointestinal Development Programs

PRESS RELEASES

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Assembly Biosciences Announces Management Transition

PRESS RELEASES

Assembly Biosciences To Present During The Jefferies Virtual Healthcare Conference

PRESS RELEASES

Assembly Biosciences Announces Move To Virtual-Only Annual Meeting Of Stockholders On June 11, 2020

PRESS RELEASES

Preclinical Data From Assembly Biosciences' Microbiome Program In Ulcerative Colitis Featured In DDW 2020 Virtual Meeting Portal And Upcoming Journal Supplements

PRESS RELEASES

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)